肿瘤细胞减灭术加腹腔热灌注化疗治疗腹膜癌62例分析  

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for 62 cases of peritoneal carcinoma

作　　者：刘玉翔 叶昱坪[2] 孙磊 王旺河 李雁 Liu Yuxiang;Ye Yuping;Sun Lei;Wang Wanghe;Li Yan(Department of Second General Surgery,Zhengzhou Yihe Hospital,Zhengzhou 450047,China;Department of Blood Transfusion,Henan Tumor Hospital,Zhengzhou 450008,China;Department of Peritoneal Cancer Surgery,Beijing Shijitan Hospital Affiliated to Capital Medical University,Beijing 100038,China)

机构地区：[1]郑州颐和医院普外二科,450047 [2]河南省肿瘤医院输血科,河南郑州450008 [3]首都医科大学附属北京世纪坛医院腹膜肿瘤外科,北京100038

出　　处：《临床医学》2021年第6期11-14,共4页Clinical Medicine

摘　　要：目的评估肿瘤细胞减灭术(CRS)加腹腔热灌注化疗(HIPEC)治疗腹膜癌病(PC)临床疗效和围术期安全性。方法选择郑州颐和医院和首都医科大学附属北京世纪坛医院2019年3月至2019年8月接受CRS+HIPEC治疗的62例PC患者的临床资料,分析生存及围术期安全性,并通过单因素和多因素分析筛选相关危险因素。结果62例腹膜癌患者接受规范性肿瘤细胞减灭术加腹腔热灌注化疗(CRS+HIPEC)治疗,中位腹膜癌指数(PCI)22分,其中PCI>20分者34例(54.8%,34/62);细胞减灭程度(CC)评分0~1者44例(71.0%,44/62)。严重不良事件(SAE)18例(29.0%,18/62):死亡(Ⅴ级)1例(1.6%,1/62),Ⅲ~Ⅳ级17例(27.4%,17/62);腹水量(P=0.014)是术后SAE的危险因素。结论腹膜癌患者接受规范性肿瘤细胞减灭术加腹腔热灌注化疗(CRS+HIPEC)治疗,可达到完全性肿瘤细胞减灭,围术期安全性可接受。Objective To evaluate the clinical efficacy and perioperative safety of cytoreductive surgery(CRS)combined with intraperitoneal hyperthermic perfusion chemotherapy(HIPEC)in the treatment of peritoneal carcinoma(PC).Methods The clinical data of 62 patients with PC who received CRS+HIPEC treatment in Zhengzhou Yihe hospital and Beijing Shijitan Hospital Affiliated to Capital Medical University from March 2019 to August 2019 were selected,and the survival and perioperative safety were analyzed,and the related risk factors through univariate and multivariate analysis were screened.Results Among the 62 PC patients that received CRS+HIPEC,the median peritoneal cancer index(PCI)was 22,and 54.8%(34/62)of the patients had a PCI>20,and 44 cases(71.0%,44/62)of the patients had CC score of 0-1;18 cases(29.0%,18/62)of the patients had serious adverse events(SAE):1 case(1.6%,1/62)died(V grade),17 cases(27.4%,17/62)hadⅢ-Ⅳgrade;ascites volume(P=0.014)was a reason of postoperative SAE(P<0.05).Conclusions PC patients treated with the standard CRS+HIPEC can achieve complete cytoreductions and may experience survival benefits with acceptable safety.

关 键 词：腹膜癌 肿瘤细胞减灭术 腹腔热灌注化疗 疗效 安全性 

分 类 号：R735.5[医药卫生—肿瘤]